Acamprosate

Evidence Level: N/A

Predicted Indications: 0

Acamprosate

Pharmacist Assessment Report

Acamprosate: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Acamprosate, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
substance abuse/dependence

Australia Market Information

Licence	Product	Dosage form	Status
8357W	Campral	Tablet (enteric coated) containing acamp	Valid

Safety Considerations

Contraindications (knowledge-graph derived, not label text): impaired renal function disease.
Drug Interactions: 15 potential interacting drugs were identified from DDInter. Severity levels were not graded, so clinical significance cannot be judged from these data. The listed drugs are:
- Pantoprazole, omeprazole, lansoprazole, ranitidine
- Doxycycline
- Prednisone, budesonide
- Simvastatin
- Lactulose
- Naltrexone
- Bupropion
- Warfarin
- Ibuprofen
- Doxepin
- Levothyroxine

Label-based warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.